Vanguard Group
CABA icon

Vanguard Group’s Cabaletta Bio CABA Stock Holding History

Vanguard Group’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$9.68M Buy
4,419,458
+228,699
+5% +$567K ﹤0.01% 2980
2025
Q3 		$9.81M Buy
4,190,759
+740,032
+21% +$1.27M ﹤0.01% 2990
2025
Q2 		$5.25M Buy
3,450,727
+606,488
+21% +$946K ﹤0.01% 3199
2025
Q1 		$3.94M Sell
2,844,239
-23,483
-0.8% -$50K ﹤0.01% 3267
2024
Q4 		$6.51M Buy
2,867,722
+314,012
+12% +$1.1M ﹤0.01% 3156
2024
Q3 		$12.1M Buy
2,553,710
+187,653
+8% +$1.09M ﹤0.01% 2863
2024
Q2 		$17.7M Buy
2,366,057
+89,835
+4% +$1.1M ﹤0.01% 2631
2024
Q1 		$38.8M Buy
2,276,222
+144,291
+7% +$3.1M ﹤0.01% 2273
2023
Q4 		$48.4M Buy
2,131,931
+163,823
+8% +$2.75M ﹤0.01% 2202
2023
Q3 		$30M Buy
1,968,108
+246,596
+14% +$3.37M ﹤0.01% 2372
2023
Q2 		$22.2M Buy
1,721,512
+607,569
+55% +$6.6M ﹤0.01% 2544
2023
Q1 		$9.21M Buy
1,113,943
+184,754
+20% +$1.73M ﹤0.01% 2981
2022
Q4 		$8.59M Sell
929,189
-349,362
-27% -$1.27M ﹤0.01% 3023
2022
Q3 		$831K Buy
1,278,551
+226,713
+22% +$273K ﹤0.01% 4060
2022
Q2 		$1.11M Hold
1,051,838
– – ﹤0.01% 4048
2022
Q1 		$2.13M Buy
1,051,838
+147,346
+16% +$385K ﹤0.01% 3927
2021
Q4 		$3.43M Buy
904,492
+173,711
+24% +$1.85M ﹤0.01% 3809
2021
Q3 		$8.89M Buy
730,781
+582
+0.1% +$5.37K ﹤0.01% 3312
2021
Q2 		$6.28M Buy
730,199
+36,314
+5% +$357K ﹤0.01% 3471
2021
Q1 		$7.7M Buy
693,885
+38,982
+6% +$476K ﹤0.01% 3304
2020
Q4 		$8.17M Buy
654,903
+81,573
+14% +$1.06M ﹤0.01% 3098
2020
Q3 		$6.21M Buy
573,330
+316,053
+123% +$3.63M ﹤0.01% 3037
2020
Q2 		$2.87M Sell
257,277
-47,116
-15% -$361K ﹤0.01% 3325
2020
Q1 		$2.22M Buy
304,393
+403
+0.1% +$5.52K ﹤0.01% 3275
2019
Q4 		$4.25M Buy
+303,990
New +$3.6M ﹤0.01% 3217

Other funds holding CABA

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Superstring Capital Management New York $140M AUM 323.19% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group's CABA Position: Q4 2025 in Review

Vanguard Group increased its Cabaletta Bio (CABA) stake by 5.5% in Q4 2025, buying an estimated $567K and bringing the position to 4,419,458 shares worth $9.68M. The position accounts for ﹤0.01% of the portfolio, ranked #2980.

Vanguard Group first reported a position in CABA in Q4 2019 and has held it in 25 quarters since. The position peaked at $48.4M in Q4 2023. 95 funds tracked by Wall St. Rank hold CABA as of Q4 2025.

  • Vanguard Group held 4,419,458 shares of Cabaletta Bio worth $9.68M as of Q4 2025.
  • Vanguard Group bought 228,699 Cabaletta Bio shares in Q4 2025, an estimated $567K.
  • Cabaletta Bio made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2980 holding.
  • Vanguard Group first reported a position in Cabaletta Bio in Q4 2019 and has held it in 25 quarters since.
  • Vanguard Group's Cabaletta Bio position peaked at $48.4M in Q4 2023.
  • 95 funds tracked by Wall St. Rank held Cabaletta Bio as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.